Regeneron’s mission is to tap into the power of genomic data to bring new medicines to patients in need. Yet, transforming this data into life changing discovery and targeted treatments has never been more challenging. With poor processing performance and scalability limitations, their data teams lacked what they needed to analyze petabytes of genomic and clinical data. Databricks now empowers them to quickly analyze entire genomic data sets quickly to accelerate the discovery of new therapeutics.
More than 95% of all experimental medicines that are currently in the drug development pipeline are expected to fail. To improve these efforts, the Regeneron Genetics Center built one of the most comprehensive genetics databases by pairing the sequenced exomes and electronic health records of more than 400,000 people. However, they faced numerous challenges analyzing this massive set of data:
Databricks provides Regeneron with a Unified Data Analytics Platform running on Amazon Web Services that simplifies operations and accelerates drug discovery through improved data science productivity. This is empowering them to analyze the data in new ways that were previously impossible.
With Databricks, the team at Regeneron no longer needs to waste excessive resources on DevOps work setting up and maintaining infrastructure to support their analytics. Today, bioinformatics teams, data scientists and computational biologists can spend more time on higher valued tasks such as developing novel new treatments.
The Databricks Unified Analytics Platform is enabling everyone in our integrated drug development process – from physician-scientists to computational biologists – to easily access, analyze, and extract insights from all of our data.”
– Jeffrey Reid, PhD, Head of Genome Informatics at Regeneron
Technical Talk at Spark + AI Summit EU 2019